December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CASI Pharmaceuticals, Inc. - Ordinary Shares (NQ:CASI)

0.8154 +0.0363 (+4.66%)
Streaming Delayed Price Updated: 10:28 AM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about CASI Pharmaceuticals, Inc. - Ordinary Shares

News headline image
CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals Announces Changes in Board Governance
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals Announces Upcoming Presentation of Clinical Results for CID-103 at the 67th American Society of Hematology (ASH) Annual Meeting
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals Appoints James Huang to Board of Directors
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) Study
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial Results
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025
Via ACCESS Newswire
News headline image
Loop Industries (NASDAQ: LOOP) Ignites Paradigm Shift – Twist™ A Breakthrough in Circular Sustainability – More Stocks Inside
Via AB Newswire
Topics Economy
News headline image
CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR)
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals Provides Business and Clinical Update
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results
Via ACCESS Newswire
News headline image
CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia
Via ACCESSWIRE
News headline image
CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results
Via ACCESSWIRE
News headline image
CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia
Via ACCESSWIRE
News headline image
BioInvent and CASI Pharmaceuticals Announce CTA Approval for Clinical Studies of BI-1206 in NHL in China
LUND, SE / ACCESSWIRE / December 10, 2021 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) , a biotech company focused on the discovery and development of novel and first-in-class... 
From BioInvent International
Via AccessWire
Global Liver Cancer Therapeutics Market Size Is Forecasted To Grow To $1.148 Billion By 2026
Via FinancialNewsMedia
Topics Death
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.